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a b s t r a c t
Prediction of lethal ventricular arrhythmias leading to sudden cardiac death is one of the most important
and challenging problems after myocardial infarction (MI). Identiﬁcation of MI patients who are prone to
ventricular tachyarrhythmias allows for an indication of implantable cardioverter-deﬁbrillator place-
ment. To date, noninvasive techniques such as microvolt T-wave alternans (MTWA), signal-averaged
electrocardiography (SAECG), heart rate variability (HRV), and heart rate turbulence (HRT) have been
developed for this purpose. MTWA is an indicator of repolarization abnormality and is currently the
most promising risk-stratiﬁcation tool for predicting malignant ventricular arrhythmias. Similarly, late
potentials detected by SAECG are indices of depolarization abnormality and are useful in risk
stratiﬁcation. However, the role of SAECG is limited because of its low predictive accuracy. Abnormal
HRV and HRT patterns reﬂect autonomic disturbances, which may increase the risk of lethal ventricular
arrhythmias, but the existing evidence is insufﬁcient. Further studies of noninvasive assessment may
provide a new insight into risk stratiﬁcation in post-MI patients.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Ventricular tachycardia (VT) and ventricular ﬁbrillation (VF)
leading to sudden cardiac death (SCD) are responsible for sig-
niﬁcant morbidity and mortality in patients with myocardial
infarction (MI). Identiﬁcation of MI patients who are prone to
VT/VF allows for an indication of implantable cardioverter-
deﬁbrillator (ICD) placement. For this purpose, there has
been an increase in research on the noninvasive risk stratiﬁca-
tion of lethal ventricular arrhythmias and SCD. To date,
various noninvasive methods such as signal-averaged electrocar-
diography (SAECG) [1–4], microvolt T-wave alternans (MTWA)
[5–7], heart rate variability (HRV) [8–10], and heart rate turbu-
lence (HRT) [11,12] have been developed, and currently, MTWA
and SAECG are widely used for risk stratiﬁcation in patients with
prior MI.
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2. Microvolt T-wave alternans (MTWA)
T-wave alternans is a periodic beat-to-beat variation in the
amplitude or morphology of the T wave on electrocardiography
(ECG) (Fig. 1). Beat-to-beat T-wave alternans is considered to reﬂect
increased dispersion of ventricular repolarization, and it is known
to often precede the development of lethal ventricular arrhythmias
[13,14]. A prior experimental study suggests that T-wave alternans
observed at rapid rates under long-QT conditions is largely the
result of alternation of the M-cell action potential duration, leading
to exaggeration of transmural dispersion of repolarization during
alternate beats [15]. MTWA testing is a noninvasive test, which can
detect subtle beat-to-beat ﬂuctuations in T-wave morphology and
amplitude using fast Fourier transform (spectral method, Fig. 2)
[16]. In general, MTWA measurement using the spectral method is
commonly performed during bicycle or treadmill exercise at an
optimum heart rate using dedicated noise-reducing electrodes, and
the development of T-wave alternans at a heart rate o110 bpm is
deﬁned as positive. MTWA testing has been found to be able to
identify patients who will beneﬁt from ICD therapy [17]. Recent
clinical trials have shown that a positive MTWA result is associated
with serious ventricular arrhythmic events and SCD [18–20]. The
ALPHA (T-wave alternans in patients with heart failure) study
demonstrated that patients who had heart failure due to idiopathic
dilated cardiomyopathy and had abnormal MTWA test results had
an adjusted hazard ratio of 3.2 for the combined primary endpoint
of cardiac death and lethal arrhythmias, whereas patients with
negative MTWA results had a good prognosis and were unlikely to
beneﬁt from ICD therapy [18]. The Risk Estimation Following
Infarction, Noninvasive Evaluation (REFINE) study showed that
combined assessment of HRT, MTWA, and left ventricular ejection
fraction (LVEF) o50% beyond 8 weeks after MI reliably identiﬁed
patients at risk of cardiac death or resuscitated cardiac arrest,
whereas that at 2–4 weeks after MI did not predict the risk of
serious cardiac events [19]. In contrast, the MATER (Microvolt
T-Wave Alternans Testing for Risk Stratiﬁcation of Post-Myocardial
Infarction Patients) trial and a prospective substudy of the Sudden
Cardiac Death Heart Failure Trial (SCD-HeFT) found that MTWA
testing did not predict arrhythmic events or mortality among
patients with left ventricular systolic dysfunction [20,21]. A recent
meta-analysis including 15 studies (5681 patients) reported that
the positive predictive value (PPV) of MTWA testing during the
mean 26-month follow-up period was 14%, negative predictive
value (NPV) was 95%, and univariate risk ratio was 2.35 [22].
According to the literature, a positive MTWA result indicated an
approximately 2.5-fold higher risk of cardiac death and life-
threatening arrhythmia, and MTWA testing showed a very high
NPV both in ischemic and nonischemic patients. It is notable that
MTWA has been reported to have a high NPV for malignant
ventricular arrhythmias after MI. Ikeda et al. reported that the
sensitivity and NPV of MTWA in predicting arrhythmic events were
very high (93% and 98%, respectively) [23]. The Alternans Before
Cardioverter Deﬁbrillator (ABCD) trial was conducted to test the
hypothesis that MTWA testing as well as invasive electrophysiolo-
gical study (EPS) should be performed to determine ICD indication
for primary prevention of SCD [24]. The trial was a multicenter
prospective study that enrolled patients with ischemic cardiomyo-
pathy and nonsustained VT. All patients underwent MTWA testing
and EPS, and an ICD was implanted if either test result was positive.
The event rates at the mean follow-up period of 1.9 years were
signiﬁcantly higher in patients with either a positive MTWA (hazard
ratio, 2.1; p¼0.03) or a positive EPS (hazard ratio, 2.4; p¼0.007)
than in those with both tests negative/indeterminate. The PPV and
NPV of the MTWA test for predicting appropriate ICD discharge or
SCD were 9% and 95%, respectively, which were comparable to the
PPV and NPV of the EPS (11% and 95%, respectively).Fig. 1. T-wave alternans (ABAB oscillation) leads to ventricular ﬁbrillation (VF).
Fig. 2. Algorithm for evaluating T-wave alternans based on the spectral method. The amplitudes of the T wave are measured for 128 beats, and the power spectrum of this
time series is described using fast Fourier transform methods. Microvolt TWA represents a peak at one-half of the beat frequency (0.5 cycles per beat).
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Recently, an alternative method of measuring T-wave alternans,
the time-domain modiﬁed moving average (MMA) method, has
been developed [25]. The MMA method applies the noise-reduction
principle of signal averaging. The T-wave amplitude and morphol-
ogy of odd and even beats were averaged for each 15-s period and
were superimposed, and the maximum difference of each median
complex was reported as the T-wave alternans values. The MMA
method allows MTWA analysis during routine 24-h Holter mon-
itoring, and a number of studies have suggested its utility for
predicting malignant ventricular arrhythmias, SCD, and cardiovas-
cular and total mortality [25–33]. The Finnish Cardiovascular Study
demonstrated that the NPV of the MMA method for SCD was 98.6%,
which was comparable to the results of a meta-analysis with the
spectral method [26,34]. The MMA method may be superior to the
spectral method in that the MMAmethod does not require a special
protocol for maintaining the stationary heart rate. Taken together,
an increasing amount of data suggests that the MTWA test is a
promising risk stratiﬁer of malignant ventricular arrhythmias. It is
currently recommended as a Class IIa, Level of Evidence A risk-
stratiﬁcation tool among post-MI patients [35].
3. Signal-averaged electrocardiography (SAECG)
SAECG is a high-resolution electrocardiographic technique
developed in the 1970s for detecting patients who are prone to
SCD after MI. It is based on the theory that lethal ventricular
arrhythmias leading to SCD often have a reentrant mechanism.
Reentry requires a unidirectional block and conduction delay
sufﬁcient to recover excitability, and areas of delayed conduction
within the infarcted ventricular myocardium can often be observed
as low-amplitude, high-frequency potentials located in the late
segment of the QRS complex by invasive EPSs (late potentials: LPs).
However, LPs are obscured by noise in a standard body surface ECG
because of their low amplitude. SAECG allows the detection of LPs
by signal averaging, which improves the signal-to-noise ratio. In
general, SAECG recordings are obtained from the Frank X, Y, and Z
leads during sinus rhythm, and a total of 200–250 cycles are
averaged to obtain a noise level of o0.2–0.4 μV. The signals are
ampliﬁed, digitized, averaged, and bidirectionally ﬁltered with a
band-pass ﬁlter at frequencies between 40 and 250 Hz. The ﬁltered
QRS duration (f-QRS), root mean square voltage of the terminal
40 ms of the ﬁltered QRS complex (RMS40), and duration of low-
amplitude signals of o40 μV in the terminal ﬁltered QRS complex
(LAS40) are measured (Fig. 3). LPs are considered to be positive if
two of the following criteria are met: (1) f-QRS4120 ms,
(2) RMS40o20 μV, and (3) LAS40438 ms [36].
To date, previous studies have reported that abnormal SAECG is
useful for identifying patients with VT after MI [37–39]. Gomes
et al. evaluated 1925 patients with asymptomatic nonsustained VT,
coronary artery disease, and left ventricular dysfunction in a
multicenter trial. An f-QRS4114 ms (abnormal SAECG) indepen-
dently predicted arrhythmic death, cardiac arrest, and cardiac
death, independent of clinical variables, cardioverter-deﬁbrillator
implantation, and antiarrhythmic drug therapy. The 5-year rates of
arrhythmic death or cardiac arrest (28% versus 17%, P¼0.0001),
cardiac death (37% versus 25%, P¼0.0001), and total mortality
(43% versus 35%, P¼0.0001) were signiﬁcantly higher in patients
with abnormal SAECG. They also assessed the prognostic utility of
SAECG at different levels of LVEF. The results showed that the
combination of an LVEF o30% and an abnormal SAECG identiﬁed
a particularly high-risk subset. It was concluded that SAECG is a
powerful predictor of poor outcomes, and the noninvasive combi-
nation of an abnormal SAECG and a reduced LVEF may help
identify high-risk patients [39]. Many studies on LPs in MI patients
were conducted before the reperfusion era [1–3]. Some investiga-
tors suggested that LPs are less common among patients after
thrombolysis and percutaneous coronary intervention, and they
limit the utility of SAECG for arrhythmia risk stratiﬁcation [40–43].
In addition, Ikeda et al. suggested that LPs were independent
predictors of sustained VT after MI but had no signiﬁcant prog-
nostic role in predicting SCD or resuscitated cardiac arrest [44].
Furthermore, we previously investigated the prevalence of LPs in
patients with VT and VF after MI. The positive rate of LPs was 92%
in VT patients and 50% in VF patients [45]. LPs may reﬂect an
arrhythmogenic substrate, which is responsible for macroreen-
trant VT and is not useful for prediction of VF. Besides, LPs are
more common in patients with inferior infarction than in those
with anterior infarction. This may be because peri-infarct tissue in
an anterior infarction is activated during the early phase of
ventricular activation, and delayed potential may be hidden within
the QRS complex.
In summary, SAECG may play an important role as a screening
test in post-MI patients because of its high negative predictive
accuracy, but its role in detecting patients at risk of lethal arrhyth-
mic events is limited by its poor positive predictive accuracy.
At present, routine use of SAECG for identifying patients at high
risk of SCD is not adequately recommended [35].
4. Heart rate variability (HRV)
HRV is a physiological phenomenon of beat-to-beat variation in
cardiac cycle length, which is inﬂuenced by autonomic tone.
Depressed HRV reﬂects autonomic disturbances, which may
increase the risk of lethal ventricular arrhythmias. In 1987, Kleiger
et al. analyzed HRV in 808 patients with MI. They found that HRV
was the strongest univariate predictor of mortality. The relative
risk of mortality was 5.3 times higher in the group with HRV
o50 ms than in the group with HRV 4100 ms. HRV remained a
signiﬁcant predictor of mortality even after adjusting for clinical,
demographic, and other Holter features and ejection fraction [8].
Since then, HRV has been widely investigated and has subse-
quently been well established as a risk factor for poor clinical
outcome in MI patients. Autonomic Tone and Reﬂexes After
Myocardial Infarction investigators evaluated the prognostic value
of HRV in post-MI patients. They found that patients with low
standard deviation of normal-to-normal relative risk (RR) intervals
(SDNN) and LVEF o35% carried an RR of 6.7 (95% conﬁdence
interval [CI], 3.1–14.6) compared with patients with LVEF 435%
Fig. 3. A representative record of abnormal signal-averaged electrocardiography
(SAECG). Signals are obtained from the Frank X, Y, and Z leads during sinus rhythm,
and a total of 200–250 cycles are averaged to obtain a noise level of o0.2–0.4 μV.
The signals are ampliﬁed, digitized, averaged, and bidirectionally ﬁltered with a
band-pass ﬁlter at frequencies between 40 and 250 Hz. The arrow indicates late
potential (LP).
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and less compromised SDNN (Z70 ms) [10]. Zuanetti et al.
assessed the prognostic value of HRV for total and cardiovascular
mortality in the ﬁbrinolytic era. All indexes of low HRV could
identify patients with a higher total mortality, and the indepen-
dent predictive value of low HRV was conﬁrmed by the adjusted
analysis [9]. Camm et al. evaluated HRV in 3717 post-MI patients
with left ventricular dysfunction. In their cohort, patients with low
HRV had a signiﬁcantly higher 1-year mortality than did those
with high HRV (15% versus 9.5%, Po0.0005), despite nearly
identical LVEF values [46]. They concluded that low HRV indepen-
dently identiﬁed a subpopulation at high risk of mortality.
Depressed HRV is currently considered a strong predictor of
mortality and lethal ventricular arrhythmias in post-MI patients,
but the evidence is lacking. Currently, HRV is recommended as a
Class IIb, Level of Evidence B risk-stratiﬁcation tool among post-MI
patients [35]. Further studies are needed to establish its role in risk
stratiﬁcation.
5. Heart rate turbulence (HRT)
HRT was introduced by Schidmt in 1999 [11]. It refers to the
physiological phenomenon in response to a premature beat. After
a ventricular premature contraction (VPC) and a compensatory
pause, there is an increase in blood pressure because of the
prolonged ﬁlling. Reﬂex parasympathetic activation accelerates
and then slows down the heart rate, which eventually returns to
normal. The relative change in RR intervals before and after the
VPC is deﬁned as HRT onset (TO), and the slope of that regression
is deﬁned as the turbulence slope (TS). To date, HRT has been
examined mainly in post-MI patients, and it is suggested that
abnormal HRT is associated with increased mortality after MI
[11,47,48]. A large prospective study validated HRT in post-MI
patients. In that study, 1455 survivors of an acute MI in sinus
rhythm were enrolled, and TO and TS were calculated from Holter
monitoring. Multivariate analysis showed that the presence of
both abnormal TO and TS was the strongest predictor of death
(hazard ratio, 5.9; 95% CI, 2.9–12.2). It was concluded that HRT is a
strong predictor of subsequent death in post-MI patients of the
reperfusion era [49]. Although HRT is currently regarded as a
strong predictor of mortality and malignant ventricular arrhyth-
mia after MI, the available evidence is insufﬁcient to support the
routine use of HRT testing in post-MI patients. Further studies are
necessary to establish its clinical utility in risk stratiﬁcation.
6. Newly developed noninvasive techniques
Deceleration capacity (DC) is a new risk stratiﬁer, which is
based on the assessment of deceleration-related modulations of
heart rate and is considered to reﬂect the vagal activity of the
autonomic nervous system. It was introduced by Bauer et al. in
2006 by using a signal-processing algorithm to separately char-
acterize the deceleration and acceleration of heart rate [50]. They
demonstrated that an impaired heart rate DC is a powerful
predictor of mortality after MI and is more accurate than LVEF
and the conventional measures of HRV.
Wavelet transform analysis is a novel time–frequency techni-
que that detects transient changes in an ECG even if they are
superimposed on the high-gain QRS complex. High-frequency
components in the QRS complex detected by this technique are
considered to reﬂect conduction abnormality hidden within the
QRS complex, which may be responsible for malignant ventricular
arrhythmias. Previously, Morlet et al. developed a wavelet-
transformed ECG for the detection of patients at risk of VT. They
found that detection of local conduction abnormality in the QRS
complex by wavelet transform was useful for VT risk stratiﬁcation
in post-infarction patients and reported 85% speciﬁcity and 90%
sensitivity for VT detection [51]. Recently, we evaluated the utility
of a wavelet-transformed ECG in post-MI patients. The sensitivity
of the abnormal high-frequency components within the QRS
complex for identifying VT/VF patients was higher than that of
SAECG (96% versus 72%), although the speciﬁcity was similar
(68.5% versus 64.3%) [44]. Furthermore, Tsutsumi et al. suggested
that the combined use of LPs and intra-QRS high-frequency
potentials hidden within the QRS complex improved the predic-
tion of lethal ventricular arrhythmias in post-MI patients [52].
7. Conclusions
Noninvasive risk stratiﬁcation techniques may be useful for
identifying patients at risk of lethal ventricular arrhythmias, but
further studies are needed. Further reﬁnement of noninvasive
studies may provide a new insight into risk stratiﬁcation in post-
MI patients.
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